HomeAI · summaries
Storia in 2 fonti
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an…
- ·
statnews.com
Immunovant shares surge on arthritis trial data
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout